Fosun Pharma: Signed a licensing agreement with Nucor to obtain the rights to develop AR1001 in China

2025-07-28 17:41:30

Fosun Pharma announced that its holding subsidiary Fosun Pharma Industry has signed a licensing agreement with Nucor, obtaining the rights to develop, register, produce and commercialize AR1001 in the agreed licensed areas (mainland China and Hong Kong and Macao) and fields (diagnosis, prevention and treatment of Alzheimer's disease and other neurological diseases). According to the agreement, Fosun Pharma Industry will pay a down payment and regulatory milestone payments of up to RMB 150 million. As of the date of this announcement, no drug with the same target for the treatment of Alzheimer's disease has been approved for marketing worldwide.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.
                            2025-07-29

                                    Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.
                            2025-07-30

                                    The world's first active safety AI battery cell goes into mass production
                            2025-07-27

                                    CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.
                            2025-07-30

                                    BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.
                            2025-08-01